MedPath

Olfactory Training in COVID-19 Associated Loss of Smell

Not Applicable
Completed
Conditions
Hyposmia
COVID-19
Registration Number
NCT05421221
Lead Sponsor
Medical University Innsbruck
Brief Summary

Olfactory dysfunction (OD) like hyposmia or anosmia has been realized as a common symptom or even cardinal sign of the disease and can be persisting after recovering.

There are two different hypotheses on the pathogenesis of OD in past COVID-19: The central hypothesis, which speculates on neurotrophic abilities on olfactory receptors in the neuroepithelium, and the peripheral hypothesis, which speculates on damage of the sensory olfactory epithelium.

Potential treatment strategies aim for the unique neural plasticity of the olfactory system and its potential for recovery.

Clinical studies and case reports have shown a promising effect of olfactory training (OT) by frequent sniffing and/or exposure to odors 2-4 times a day for several weeks.

The main objective of the study is to assess the effects of olfactory training in patients with COVID-19 related OD on:

1. objective olfactory testing with the Sniffin' sticks test (identification and discrimination),

2. subjective OD and its impact on the daily life,

3. other clinical scales and questionnaires referring to OD-related mood and quality of life,

4. gender differences in COVID-19 related OD. Approach / methods OT will be performed twice a day with a 4-odor training set for 12 weeks. Effects of OT on COVID-19 related OD will be measured with objective and subjective efficacy variables.

The sense of smell is an important function for social relationships and is therefore a challenging clinical problem with few proven therapeutic options.

With this new approach, we want to investigate a possible simple treatment for an impedimental symptom of COVID-19, but also learn more about the pathomechanism of post-infectious OD.

To our knowledge, this will be the first study comparing patients with COVID-19 associated OD with and without OT in clinical outcomes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • The subject is aged over 18 years;
  • confirmed diagnosis of COVID-19 at least three months ago (history of positive PCR-testing required) or positive serum nucleocapsid antibody titer against SARS-CoV2;
  • post-infectious COVID-19 related olfactory dysfunction persisting for at least three months with abnormal Sniffin' sticks test (<13/16 items correct in the identification part);
  • the patient is willing to undergo odor training over 12 weeks;
  • written ICF is obtained.
Exclusion Criteria
  • History of olfactory dysfunction prior to COVID-19 infection due to other conditions e.g. status post traumatic brain injury, Parkinson's disease, allergic rhinitis, etc.;
  • Nasal pathology not related to COVID-19 in the systematic otorhinolaryngological examination including endoscopy.
  • the participant is pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
primary endpoint12 weeks

changes between groups from baseline to week 12/termination visit regarding correct odor identification and discrimination

Secondary Outcome Measures
NameTimeMethod
Visual Analog Scale12 weeks

from 0 to 10, higher score means better subjective olfaction

Hospital Anxiety and Depression Scale12 weeks

Anxiety and Depression Each item is scored on a 4-point scale from 0 to 3; lower scores mean less anxiety/depression

Clinical treatment response over time12 weeks

Using Clinical Global Impression of Improvement

Short-Form-36 Health Survey Questionnaire (SF-36)12 weeks

Quality of Life Each domain is scored from 0 to 100, higher scores mean better health status

Mood inventory12 weeks

Will be applied in German

Patient Progress and treatment response over time12 weeks

Using Patient Global Impression of Improvement

Trial Locations

Locations (1)

Medical University of Innsbruck

🇦🇹

Innsbruck, Tirol, Austria

Medical University of Innsbruck
🇦🇹Innsbruck, Tirol, Austria

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.